secwatch.observer — SEC 8-K summary
======================================

Issuer:     Matinas BioPharma Holdings, Inc. (MTNB)
CIK:        0001582554
Form:       8-K
Filed at:   2023-12-27T23:59:59+00:00
Accession:  0001493152-23-046183
Event type: other_material
Sentiment:  positive
Materiality: 0.55
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Matinas reports oral LNC-oligonucleotides show TNFα reduction in colitis model; psoriasis markers improve
--------------------------------------------------------------------------------

- Orally LNC-formulated small oligonucleotide targeting TNFα reduced serum TNFα by 37% in DSS-induced colitis model.
- Active LNC formulation significantly improved clinical disease activity scores at key time points in colitis study.
- In IMQ-induced psoriasis model, LNC-delivered IL-17A oligonucleotide lowered skin tissue IL-17A mRNA and improved redness/scaling.
- Plans to present additional tissue/histologic analyses at future scientific meetings.
- CEO highlights potential for oral delivery of extra-hepatic small oligonucleotides as differentiating platform feature.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223046183/0001493152-23-046183-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1582554/000149315223046183/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-046183

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer